Home › Burkitt Lymphoma › Maryland › Baltimore
Burkitt Lymphoma clinical trials in Baltimore, MD
8 studies for Burkitt Lymphoma are looking for participants at sites in and around Baltimore (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RecruitingPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
- Johns Hopkins Asthma & Allergy Center, Baltimore
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 1
- University of Maryland, Baltimore
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RecruitingPhase 1
- University of Maryland, Baltimore
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Milwaukee, WI16 studies
- Philadelphia, PA16 studies
- New York City, NY14 studies
- Chicago, IL14 studies
- Cincinnati, OH12 studies
- Atlanta, GA12 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Boston, MA10 studies
- Kansas City, MO10 studies
- Aurora, CO10 studies
Other studies in Baltimore
- Non-Small Cell Lung Cancer60 studies
- Breast Cancer47 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Cancer (all types)37 studies
- Colorectal Cancer31 studies
- Pancreatic Cancer31 studies
- Metastatic Cancer28 studies
- Obesity25 studies
- Heart Failure24 studies
- Bladder Cancer24 studies
- Stroke22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.